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Radiation therapy is one of the most commonly used treatments for cancer. The dose of
delivered ionizing radiation can be amplified by the presence of high-Z materials via an
enhancement of the photoelectric effect; the most widely studied material is gold (atomic
number 79). However, a large amount is needed to obtain a significant dose enhancement,
presenting a challenge for delivery. In order to make this technique of broader applicability,
the gold must be targeted, or alternative formulations developed that do not rely solely on
the photoelectric effect. One possible approach is to excite scintillating nanoparticles with
ionizing radiation, and then exploit energy transfer between these particles and attached
dyes in a manner analogous to photodynamic therapy (PDT). Doped rare-earth halides and
semiconductor quantum dots have been investigated for this purpose. However, although
the spectrum of emitted light after radiation excitation is usually similar to that seen with
light excitation, the yield is not. Measurement of scintillation yields is challenging, and
in many cases has been done only for bulk materials, with little understanding of how
the principles translate to the nanoscale. Another alternative is to use local heating using
gold or iron, followed by application of ionizing radiation. Hyperthermia pre-sensitizes the
tumors, leading to an improved response. Another approach is to use chemotherapeutic
drugs that can radiosensitize tumors. Drugs may be attached to high-Z nanoparticles or
encapsulated. This article discusses each of these techniques, giving an overview of the
current state of nanoparticle-assisted radiation therapy and future directions.
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INTRODUCTION AND BACKGROUND
Radiation therapy (XRT) is a critical component of the mod-
ern approach to curative and adjuvant treatment of cancers.
XRT controls the growth of cancerous cells by bombardment
with ionizing radiation, causing DNA damage by direct ion-
ization or through generation of free radicals by ionization of
water or oxygen molecules. Sufficient damage to DNA in this
fashion can arrest cell growth and prevent metastasis. The pri-
mary drawback is collateral damage: there is little distinction
in absorption between healthy and malignant tissues, and thus
doses must be limited in order to mitigate unwanted dam-
age to the tumor surroundings. External beam radiotherapy
(EBRT) utilizes X-ray beams produced by orthovoltage units, or
linear accelerators that may be spatially oriented, with beams
shaped using multileaf collimators in order to maximize the
specificity for the target. Distinct energy ranges are available
for different EBRT targets: 40–100 kV (kilovoltage or “super-
ficial” X-rays) for skin cancers or other exposed structures;
as well as 100–300 kV (orthovoltage) and 4–25MV (mega-
voltage or “deep” X-rays) for sub-surface tumors. Techniques
such as 3-dimensional conformal and intensity-modulated radi-
ation therapies have vastly improved the targeting capabilities
of external beam therapy, but naturally there is still a strong
desire to be able to further reduce the doses required for
effective treatment. The SI derived unit for absorbed dose is
the gray (Gy), equivalent to one joule of energy deposited by
ionizing radiation per kilogram of matter (1Gy = 1 J/kg =
1m2/s2).
Brachytherapy, or internal radiotherapy, utilizes a radioactive
source to provide a steady or pulsed dose of radiation to a small
tissue volume. It is typically used for cervical, prostate, breast and
skin cancers. Radioactive sources include 125I and103Pd, which
produce γ rays of ∼20–35 keV, 192Ir (γ rays, 300–610 keV), 137Cs
(γ rays, 662 keV), 60Co (γ rays, 1.17 and 1.33MeV), 198Au (γ rays,
410–1009 keV), 226Ra (γ rays, 190–2430 keV), and 106Ru which
decays primarily through β− emission at 3.54MeV. Seeds of the
listed materials can provide doses of up to 12Gy/hour (high dose
rate or HDR brachytherapy), though typical low dose rate (LDR)
treatments amount to around 65Gy over 5–6 days.
Heavy elements can be potent radiosensitizers (Kobayashi
et al., 2010). It has been demonstrated that platinum-containing
DNA-crosslinking drugs such as Cisplatin can enhance the effects
of ionizing radiation through the “high Z effect,” or what has
come to be known as Auger therapy. Heavy elements have sig-
nificantly higher photoelectric cross-sections than soft tissue for
sub-MeV energies, approximated for “X-ray energies” by the
equation:
σpe ∝ Z
n
E3
where σpe is the cross-section, E = hν is the photon energy, Z
is the atomic number, and n varies between 4 and 5 depending
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on the value of E. The photoelectric effect dominates below
the electron rest energy of 511 keV, beyond which inelastic
Compton scattering becomes more prevalent. As the photon
energy decreases, it is no longer able to eject inner-shell electrons,
producing the characteristic sawtooth pattern with K, L, andM
edge structures. When ionized by X-ray or γ ray energy, mid- to
high-Z elements (roughly Br and up) can produce a cascade of
low-energy Auger electrons that can locally enhance the effective
radiation dose (Kobayashi et al., 2010). Dense inorganic nanopar-
ticles can also provide radiation dose enhancement that depends
upon the composition and size of the particles, uptake of particles
into cells, and the energy of the applied radiation.
GNRT
Au nanoparticles have been under investigation for several years
as possible agents for selective amplification of radiation dose
in tumors, a concept called “gold nanoparticle-assisted radiation
therapy” or GNRT (McMahon et al., 2008; Brun et al., 2009;
Cho et al., 2009; Rahman et al., 2009; Van den Heuvel et al.,
2010; Leung et al., 2011; Zhang et al., 2012). Reviews of this work
can be found in Jelveh and Chithrani (2011), Butterworth et al.
(2012), Jain et al. (2012), Babaei and Ganjalikhani (2014), Su et al.
(2014).
The earliest studies used bulk or micro-sized gold to enhance
radiation dose. Although this could be effective in vitro at a
range of energies, micron-sized particles are not taken up well
in vivo, even after intratumoral injection (Herold et al., 2000).
Later experiments focused on Au nanoparticles or nanoclusters
(1.9 nm diameter). When injected intravenously, these ultrasmall
particles rapidly accumulated in cancer tissue, with 2.7 g Au/kg
body weight resulting in 7mg Au/g in tumor almost immedi-
ately after injection. Irradiation was performed about 60 s after
injection, and with typical 250 kVp X-ray therapy, 1-year survival
was 86% (compared to 20% with X-rays alone and 0% with gold
alone) (Hainfeld et al., 2004). This result was followed by theo-
retical and experimental papers examining the mechanism of Au
nanoparticle action as well as attempting to optimize Au parti-
cle concentration, size, and the energy and dose of applied X-rays
(Cho et al., 2009; Zhang et al., 2009; Van den Heuvel et al., 2010;
Leung et al., 2011).
IMPROVING GNRT BY TARGETING
A significant problem with ultrasmall, nontargeted nanoparticles
is rapid excretion by the kidneys. The amount of Au needed in
early studies (>2 g Au/kg body weight) represents a very large
amount of Au for human use. This is impractical, costly, and
may cause toxicity. Achieving therapeutic levels in tumor with less
delivered total Au is needed. In addition, irradiation in the mouse
studies was performed immediately after particle injection. This
is not practical in the clinic and may not work well in humans.
Particles with longer circulation times, which can be delivered in
multiple doses, are desirable for clinical applications. Optimizing
the size, surface chemistry, and targeting of the Au nanoparti-
cles may improve circulation times and accumulation in specific
tumors.
The increased metabolic rate of tumors relative to normal tis-
sue results in a high demand for glucose. Several studies have used
FIGURE 1 | Approaches to creating tumor-targeted Au nanoparticles.
Molecules not to scale. (A) Thioglucose-conjugated Au nanoparticles.
(B) Au nanoparticles conjugated to Herceptin (anti-HER2 antibody). (C) Au
nanorods conjugated to folic acid. (D) PEI-coated Au nanoparticles
conjugated to choline.
thioglucose-conjugated Au nanoparticles (Figure 1A) in order
to increase uptake by cancer cells. One study using ∼14 nm
Au demonstrated significantly increased uptake of thioglucose-
conjugated particles by an ovarian cancer cell line after 8–96 h of
incubation (Geng et al., 2011). A significant increase in inhibi-
tion was seen in the presence of 5 nM particles using 90 kVp or
6MV X-rays; dose enhancement was significant relative to con-
trol beginning at 5Gy and extending to 20Gy, where all cells were
inhibited even in the absence of particles. Another study com-
pared cysteamine and thioglucose-coated 15 nMAu nanoparticles
in breast cancer and normal breast cell lines (Kong et al., 2008b).
Cysteamine-coated particles were taken up 3- to 4-fold more effi-
ciently than glucose-coated particles. However, when applied to
cells at concentrations that led to similar intracellular Au con-
centrations, glucose-coated particles led to increased radiosen-
sitization relative to cysteamine-capped particles. Interestingly,
radiosensitization by Au was not seen in a nonmalignant breast
cell line, although the cells grew at the same rate as the cancer cells
and took up an equal number of particles. The ability of 167Cs and
60Co sources to inhibit the cancer cells was also demonstrated in
this paper.
The use of larger Au particles (57 nm and 84 nm) coated with
thioglucose has been studied in another report (Song et al., 2013).
These particles were taken up in equal numbers by HeLa cells.
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Surprisingly, unconjugated particles showed a greater radiosen-
sitizing effect than thioglucose-conjugated particles, which the
authors attributed to possible absorbance of singlet oxygen by the
thioglucose shell.
Another study used the humanized anti-HER2 antibody
Trastuzumab (Herceptin), PEGylated and conjugated to 30 nm
Au particles, for delivery to MDA-MB-361 breast cancer
(Chattopadhyay et al., 2013) (Figure 1B). Both in vitro and in vivo
studies were performed. In vitro, an effective dose enhancement
factor of 1.6 was seen in the presence of 2.4mg/mL particles using
100 kVp X-rays. Delivery to MDA-MB-361 xenografts was done
intratumorally, with ∼0.8mg total Au used (4.8mg/g tumor).
11Gy of 100 kVp image guided X-ray irradiation was performed
24 h after injection. This subtoxic dose led to a 46% reduction in
tumor size relative to irradiation alone, with no damage to normal
tissue or systemic toxicity.
Folic acid is another nutrient for which the need is increased in
cancer cells. Conjugation to folate has been used for a wide variety
of targeting applications for cancer and inflammatory diseases;
a review may be found here (Low et al., 2008). Intra-operative
tumor imaging using folate targeting has recently moved to
the clinic for ovarian cancer (van Dam et al., 2011). In terms
of GNRT, one study reported the use of silica-modified Au
nanorods (∼50 nm long) conjugated to folate (Huang et al., 2011)
(Figure 1C). The rods were taken up by MGC803 human gas-
tric carcinoma cells. 6 Gy of X-irradiation led to a 60% decrease
in cell viability in the presence of 12.5μM rods relative to cells
without Au. The study also demonstrated uptake of the rods
by MGC803 xenografts in nude mice, with contrast sufficient
for X-ray imaging. No radiation experiments on animals were
reported.
Cancers are also often distinguished by a lower pH than
healthy cells due to hypoxia and resulting anaerobic metabolism
within tumors. The pH-sensitive pHLIP peptide was used in
one study to target Au nanoparticles to mice bearing HeLa
tumors (Yao et al., 2013). Although radiation was not per-
formed, accumulation of Au in tumors sufficient for radiotherapy
enhancement was demonstrated, with the stated goal of using the
construct for this purpose.
Prostate cancer is an excellent target for nanoparticle-
enhanced radiation, since it is often treated by brachytherapy and
is accessible to intratumoral injection. Choline is a ubiquitous
molecule in all cells for which overactivity of processing enzymes
(choline kinase) has been found in prostate tumors. One study
reported development of polyethylene imine (PEI)- and choline-
conjugated Au nanoparticles for the purpose of targeting prostate
cancer for GNRT (Razzak et al., 2013) (Figure 1D). While no
radiation experiments were performed in this study, favorable
pharmacokinetics were shown in mice.
These studies illustrate that targeted GNRT remains an area
requiring substantial further investigation. While one or more
targeting agents may be conjugated to Au nanoparticles, and
while these may improve delivery in vitro and even in vivo, it is
not fully established whether these formulations improve tumor
response to radiation therapy. The possibility that an organic shell
can absorb reactive oxygen species deserves further inquiry. The
size of the nanoparticles used, the density of targeting ligands,
and the delivery method (IV, intratumoral, concentration, tim-
ing) all need to be optimized. The good news is that many of these
formulations use FDA-approved ingredients, some of which are
currently in the clinic for imaging. Optimization in animal studies
should thus lead to rapid clinical translation.
IMPROVING GNRT BY ADDITION OF PHOTOTHERMAL THERAPY
Hyperthermia therapy is a minimally invasive treatment in which
the temperature is increased locally (up to 44◦C) to kill malig-
nant cells. Even though hyperthermia can kill cells on its own,
it is more often used in combination with other treatments such
as radiotherapy or chemotherapy (Wust et al., 2002); such com-
binations are in clinical trials (Vernon et al., 1996; van der Zee
et al., 2000; Zagar et al., 2010). An increase in nuclear damage
is one of the mechanisms through which cells are radiosensi-
tized after hyperthermia (Wust et al., 2002; Kampinga, 2006). In
addition, the higher temperature causes dilation of the blood ves-
sels, increasing oxygenation of the tumor (Griffin et al., 1996;
Song et al., 2009). Since oxygen is a potent radiosensitizer, it
can increase the damage to the tumor through generation of free
radicals.
Methods to locally heat the tumor region include high inten-
sity focused ultrasound (HIFU), microwave heating, magnetic
hyperthermia, and photothermal therapy. In photothermal ther-
apy, a light source (usually infrared) is used to deliver heat to
the tumor. Such approaches are difficult to target, but delivery of
nanomedicines to the tumor could improve the local heating pro-
file. Most studies have looked at gold nanoparticles and nanorods
for this purpose, because exposure of Au nanoparticles to IR light
causes a local temperature increase due to surface plasmon res-
onance (El-Sayed et al., 2006; Huang et al., 2006; Gobin et al.,
2007; Hainfeld et al., 2010; Verma et al., 2014). By modifying the
size and shape of these nanoparticles, the resonance peak can be
tuned to different wavelengths in the IR.
Delivery of gold followed by heating and ionizing radiation
has proved to be a promising approach in pre-clinical studies.
Gold nanoshells with a 120 nm silica core and a 12–15 nm shell
were used in one study (Diagaradjane et al., 2008) to treat a
murine xenograft model of human colorectal cancer. Localized
hyperthermic treatment followed 5min later by a 10Gy X-ray
dose were given 20–24 h after IV delivery of the nanoshells. The
tumor volume doubling time was significantly greater for the
treated mice. Two mechanisms were identified as contributing to
the treatment’s efficacy: an increase in perfusion resulting in a
decrease in tumor hypoxia, and vascular collapse in the tumor
due to accumulation of nanoparticles around the blood ves-
sels. Another study confirmed these results using similar gold
nanoshells in two murine breast cancer models (Atkinson et al.,
2010).
Another study used gold nanorods modified with silica and
conjugated to folic acid (Huang et al., 2011) to test the effects of
photothermal and radiation therapy on MGC803 gastric cancer
cells. The two treatments were tested separately and not com-
bined. For the radiation treatment, a 6MeV source was used to
deliver doses of up to 10Gy. Cell survival with radiation decreased
in a concentration-dependent fashion with nanoparticle addi-
tion; the particles were non-toxic in the absence of radiation.
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Photothermal therapy consisted of 3min of irradiation with a
30mW, 808 nm laser source. Apoptosis was seen after treatment
in the presence of the gold particles.
A recent study (Hainfeld et al., 2010) calculated the radiation
dose required to control 50% of tumors (TCD50) in a mouse
squamous cell carcinoma model. Gold nanoparticles were deliv-
ered intratumorally, and 24 h later the tumor was heated to 48◦C
for 5min at 1.5W/cm2 followed by X-ray irradiation at 100 kVp
(7.5Gy/min). TCD50 was reduced from 55Gy to less than 15Gy.
These studies illustrate one of the biggest problems of the
approach, which is the need for simultaneous delivery of heating
and radiation, which poses logistic problems in the clinic (Wust
et al., 2002). Other drawbacks include a lack of specificity and the
difficulty of heating deep tumors.
ALTERNATIVES TO GOLD: BISMUTH AND IRON
Alternatives to Au are being sought that are more effective and/or
less costly. Bismuth (Bi, Z = 83) and platinum (Pt, Z = 78) have
been shown in at least one theoretical study to yield a dose
enhancement factor higher than Au, with Bi being the high-
est. Dose enhancement is predicted to increase with decreasing
nanoparticle size, because the smaller nanoparticles accumulate
closer to the nucleus, where they can cause the greatest damage.
The dose enhancement is also expected to be greater when the
average energy is close to the K-edge of the element (Ngwa et al.,
2010; Hossain and Su, 2012). A radiochromic dosimeter was used
in another study to experimentally measure the dose enhance-
ment of bismuth oxide (Bi2O3) nanoparticles. Using a 100 kV
X-ray source and an irradiation dose of 10Gy, the radiation dose
in a water-equivalent matrix doped with 0.5mM of 50 nm Bi2O3
nanoparticles was >80% higher than in the control compart-
ment (Alqathami et al., 2013). Another study (Zhang et al., 2014)
looked at the dark toxicity, biodistribution, and radiation effects
of bismuth selenide (Bi2Se3) nanoplatelets in cell lines and mice.
The platelets were not significantly toxic to either cells or mice,
with over 93% of the Bi cleared from the body 90 days after treat-
ment. Significant radiation dose enhancement was observed after
irradiation doses of up to 8Gy.
Gadolinium (Gd, Z = 64) represents another alternative to
gold nanoparticles. In addition to having a relatively high atomic
number, Gd is already routinely used as a contrast agent in MRI.
Gd2O3 core nanoparticles encapsulated in a polysiloxane shell
have shown potential as an image guided radiotherapeutic tool
in a gliosarcoma rat model (Le Duc et al., 2011). Accumulation
of the nanoparticles in the tumor after saphenous vein injec-
tion was demonstrated using MRI, and the tumor-bearing rats
were treated with microbeam radiation therapy, with a significant
increase in survival in the nanoparticle-treated group. Another
study using a rat brain tumor model confirmed that ultra-small
Gd-based nanoparticles accumulate in brain tumors after IV
injection (Miladi et al., 2013).
Magnetic particles such as iron oxide may also be used for
combined hyperthermia and radiation. By using an alternating
magnetic field to excite magnetic nanoparticles, local temperature
increases can be achieved. The advantages of iron oxide include
low toxicity, ease of synthesis, and the ability to perform image
guidance using MRI. Dextran-coated iron oxide has been shown
to reduce tumor growth in a syngeneicmouse breast cancermodel
when hyperthermia and radiation were combined (Giustini et al.,
2011).
Several studies have looked at radiosensitization properties
of iron oxide nanoparticles. Using 6MeV X-rays on a human
prostate carcinoma cell line (DU145), 1mg/ml of Fe3O4 nanopar-
ticles resulted in a dose enhancement factor of approximately 1.2
(Khoei et al., 2014). Another study suggested that superparamag-
netic iron oxide nanoparticles (SPIONs) can radiosensitize tumor
cells by catalyzing ROS formation. Uncoated, citrate-coated, or
malate-coated SPIONs were added to MCF-7, 3T3, and Caco-2
cells. Uncoated SPIONS caused dark toxicity, with no increase
in ROS upon 1 or 3Gy irradiation. In contrast, coated SPIONS
were non-toxic in the absence of radiation, but resulted an
increase of up to 300% in the fluorescence intensity of the ROS
reporter dichlorofluorescein diacetate (DCF-DA) (Klein et al.,
2014).
SCINTILLATING NANOPARTICLES FOR
RADIATION/PHOTODYNAMIC “HYBRID” THERAPY
INTRODUCTION AND CONCEPT
A 2006 study proposed a new approach to nanoparticle-based
therapies aiming to combine and enhance the effects of radi-
ation therapy and photodynamic therapy (PDT) through the
use of scintillating nanoparticles conjugated to photosensitizer
molecules (Chen and Zhang, 2006). The concept is simple: attach
a dye used for PDT to a nanoparticle that emits light when excited
by therapeutic radiation (scintillates). If the scintillation emission
overlaps the absorbance spectrum of the dye, the dye will generate
singlet oxygen as it does with light-excited PDT (Figure 2). Many
conventional photosensitizers are based on naturally occurring
porphyrin, chlorin, and bacteriochlorin structures comprised of
highly conjugated heterocyclic macrocycles (Figure 3A). These
molecules have a strong absorbance peak in the UV to blue range
(Soret band) as well as numerous weaker peaks in the visible
(Figure 3B).
This idea has attracted significant attention over the past few
years (Cheng and Lo, 2011) because it promises to combine the
tissue penetration depth of radiation with the efficacy and benign
side effect profile of PDT. PDT results in less damage to normal
tissue than does radiation therapy; does not induce scarring; may
be repeated multiple times; and may spark immune responses
that help destroy the tumor. However, because of the limited
tissue penetration depth of visible and even near-IR light, this
therapy is restricted to only the most superficial cancers, such as
non-melanoma skin cancer and bladder cancer.
The challenge is to develop stable, nontoxic nanoscintillators
that may be delivered to cells. Several varieties of doped insula-
tor and semiconductor nanoparticles have been proposed to fill
this role. While scintillation has been demonstrated for CdSe/ZnS
quantum dots (Létant and Wang, 2006), they have poor radia-
tion hardness and degrade rapidly under γ ray exposure (Withers
et al., 2008). As the toxicity of these materials is also primarily
related to their chemical degradation, alternatives are necessary.
The development of such alternatives is mostly in early stages.
Although many of the approaches to surface chemistry and tar-
geting that have been used for gold could be applied to these other
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FIGURE 2 | Schematic of photodynamic therapy and
radiotherapy-photodynamic therapy “hybrid” approach. (A) In
photodynamic therapy, photosensitizer dye molecules collect preferentially
in malignant or inflamed tissue. Light is used to excite the dye, generating
reactive oxygen species which lead to cell killing. (B) In the “hybrid”
approach, ionizing radiation is used to excite scintillating nanoparticles,
which may be located deep within tissue. The nanoparticles transfer energy
to attached photosensitizer molecules, generating ROS and killing cells by
the same mechanism as photodynamic therapy.
materials, this has not yet been attempted. Some of the materials
also show specific chemical challenges as we will discuss in Section
Biocompatibility of lanthanide-based materials.
SCINTILLATION
Scintillation, or radioluminescence (RL), is the process whereby
a material, referred to as a scintillator, produces light upon
interaction with ionizing radiation. Inorganic nanoparticles
(NPs) doped with lanthanides present an attractive, radiostable
alternative to quantum dots for scintillation.
Introduction to lanthanide luminescence
Lanthanides are well known for the luminescence of their triva-
lent cations, which emit primarily through phosphorescence
resulting from electronic transitions within the 4f shell (Bünzli
and Eliseeva, 2010). Because these transitions are “forbidden”
by Laporte’s parity selection rule (formally prohibiting electric
dipole transitions between states that conserve parity), they have
low absorption cross-sections and their photoluminescence is
commonly sensitized by Ce3+ (for downconversion, with Tb3+
acceptor) or Yb3+ (for upconversion, with Tm3+, Er3+, andHo3+
acceptors), though more complex combinations of lanthanides
are certainly possible. The efficiency of both processes benefits
FIGURE 3 | Photosensitizers. (A) Typical photosensitizer structures:
mono-L-aspartyl chlorin e6 (Talaporfin sodium), a PDT drug that can be
isolated from algae or green plants (approved in Japan and in Phase III trials
in the U.S.); deuteroporphyrin IX, a candidate photosensitizer with several
possible derivatives. (B) Absorbance spectra of different concentrations of
deuterophorphyrin IX disulfonic acid (DPIX-DS). Note the strength of the
Soret band (UV-blue) compared to the peaks in the redder regions.
from a low phonon energy host, though is of increasing impor-
tance for lower energy transitions. In the case of upconverting
NPs, hexagonal phase (β phase) NaYF4 or isostructural NaGdF4
are generally the preferred host materials.
The mechanism of cerium luminescence is distinct from most
other lanthanides. Neutral cerium has a [Xe]4f15d16s2 electronic
configuration; in solution or in solid hosts, the +3 or +4 oxi-
dation states are the most common. Only the +3 state is lumi-
nescent, though the +4 state also has important implications
for redox activity. In the +3 state, the 6s and 5d electrons are
lost, leaving one optically active electron in the shielded 4f shell.
Fluorescence (S = 0) arises from parity-allowed, high oscillator
strength 4f -5d transitions. Because the 5d orbitals are external,
these transitions are sensitive to the crystal field, and vary in
energy across a substantial range depending on the host material
(Dorenbos, 2000).
Cerium-doped lanthanum fluoride (CexLa1−xF3) shows lumi-
nescence in the UV-blue (corresponding well to the Soret
band) and so is a likely candidate for useful energy transfer to
photosensitizers.
Mechanisms of scintillation
RL mechanisms of bulk CexLa1−xF3 crystals were elucidated in
the late 80 s and early-to-mid 90 s as candidates for radiation
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detection purposes (Moses and Derenzo, 1989, 1990; Wojtowicz
et al., 1992, 1994; Lempicki et al., 1993; Moses et al., 1994; Rodnyi
et al., 1995). Though the scintillation was found to be significantly
faster than commonly used scintillators at the time (BGO, CsI:Tl,
NaI:Tl) on a per-photon basis, the overall light output was found
to be unexpectedly weak, with variable luminescence that was sig-
nificantly dependent on the quality of the crystal and the presence
of defects. This variability precluded their use as reliable detec-
tors for the most part, at least compared to other options being
developed concurrently, such as PbWO4.
The general process of activator-based scintillation occurs in
three steps: first, conversion of absorbed ionizing radiation energy
into electronic-lattice excitations (electron-hole pairs and/or exci-
tons), followed by transfer of the excitation energy to the emitting
centers and then luminescence. The overall scintillation efficiency
is given by the product of the individual efficiencies:
η = βSQ, 0 ≤ η, β, S,Q ≤ 1
where β, the efficiency of the conversion process, encompasses
the fraction of absorbed energy lost to optical phonons, S is the
efficiency of the transfer process, andQ is the luminescence quan-
tum yield of the emitting center. The overall light output L (in
photons/MeV) is given by:
L = ne−hη = 10
6
2.3Eg
βSQ
where ne−h is the number of e-h pairs or excitons that are gener-
ated per MeV of absorbed radiation, discounting losses to optical
phonons, and Eg is the band gap of the host (in eV). The fac-
tor of 2.3 is related to the derived minimum incident photon
energy required to generate a single e-h pair (Robbins, 1980),
ξmin = 2.3Eg , and so ne−h = E/2.3Eg where E is the energy of the
incident photon, in this case 1MeV = 106 eV.
Low phonon energy hosts such as LaF3 tend toward higher
values of β, while the transfer process S is relatively inefficient
compared to pentaphosphate or orthophosphate hosts (Lempicki
et al., 1993). The β and S mechanisms of CexLa1−xF3 were deter-
mined to consist of three distinct processes that have different
relative contributions depending on the value of x: (i) direct exci-
tation of Ce3+ by X-rays or secondary electrons, (ii) ionization of
Ce3+ followed by electron capture and formation of bound exci-
tons, or (iii) energy transfer to Ce3+ from lattice excitations of
the bulk matrix. At lower concentrations of Ce3+, up to x ∼ 0.5,
mechanism (iii) dominates the scintillation response. At higher
doping levels, mechanism (i) is predominant, accounting for a
large fraction of the light output in CeF3. It has recently been
demonstrated that co-doping single crystals of YPO4:Ce3+ with
Pr3+, which act as electron traps, can improve scintillation effi-
ciency by minimizing the influence of defects as well as mitigating
the effects of damage caused by prolonged irradiation (Moretti
et al., 2014).
Nanoscintillators
A number of reports have investigated the scintillation response
of CexLa1−xF3 nanocomposites, where small NPs (∼10 nm in
diameter) are cast into oleic acid or polymer matrices with
consistencies ranging from liquid to waxy. In initial studies,
nanocomposites exhibited photopeaks for 137Cs, 241Am, and
57Co irradiation (McKigney et al., 2007a,b). Most recently, a
modest scintillation response (compared to a BC-400 polyvinyl-
toluene detector) has been shown for 25% NP-loaded composites
exposed to several sources: 22Na (3.22μCi), 60Co (3.78μCi),
137Cs (31.9μCi), 241Am (9.09μCi), and 252Cf (5.03μCi) (Guss
et al., 2013). For radiation detection purposes, fast lifetimes are
typically preferred, whereas for bioconjugates, short lifetimes
may preclude efficient energy transfer if it is outcompeted by
luminescence or quenching processes.
While the scintillation of cerium in simple fluoride or phos-
phate hosts is well studied, it is just one of a number of pos-
sible scintillation mechanisms. In the late 2000 s, a number of
reports were released discussing the possibilities and limitations
for nanoscintillators in a broad sense, including the demon-
stration of a few crucial nanoscale phenomena (Klassen et al.,
2008, 2009; Dujardin et al., 2010; Kortov, 2010). Several research
groups are now engaged in the development of a wider variety
of nanoscintillators, either through adaptation of known scin-
tillating materials to the nanoscale, or through the creation of
novel compositions. Many of these are based on luminescent
“activator” dopants, including lanthanides (Ce3+, Pr3+, Tb3+, or
Eu2/3+). RL spectra have been published for a number of fluo-
ride nanoscintillators, including powdered LaF3:Eu (∼4.4 nm),
BaF2:Ce (∼10 nm), and CaF2:Eu (∼18 nm) NPs under excita-
tion by a 40 kV Bullet X-ray tube and CaF2:Eu3+ excited by a
1μCi 241Am source (Eα = 5.5 MeV, Eγ = 60 keV) (Jacobsohn
et al., 2011). The authors suggest that in such doped ionic crystals,
where the diffusion length of e-h pairs may be up to 100 nm, it is
conceivable that scintillation yields may be limited by the phys-
ical dimensions of the NPs or by the total number of activators.
The same group has also compared the effects of undoped LaF3
shell thickness on the photoluminescence vs. RL of LaF3:Eu NPs
(Jacobsohn et al., 2010). The undoped shells act as a passivating
barrier that is transparent to both optical excitation and emis-
sion, and PL efficiency was found to increase in a roughly linear
fashion as a function of overall NP size as additional shells were
added. With X-ray excitation, the shells were found to increase
RL efficiency up to a shell volume of roughly twice the core vol-
ume, beyond which the light yield decreased with additional shell
thickness. This was attributed to the increased undoped volume
decreasing the probability of radiative recombination within the
Eu-doped core volume, and suggesting that the diffusion length
of carriers in LaF3 to be relatively short.
Indeed, the luminescence of core-only activator-based
nanoscintillators has been found to be size-dependent in some
cases. One study demonstrated a considerable broadening of
Eu3+ emission lines in progressively smaller Gd2O3 NP hosts as
compared to bulk crystals, attributed to increasing crystal field
fluctuations in the smaller NPs (Dujardin et al., 2010). A number
of physical mechanisms potentially influencing nanoscintillators
are described in the report, including structural effects, surface
effects, quantum confinement, and dielectric confinement. Also
shown was a significant difference in the RL spectra of bulk
vs. nanoscale CeF3 samples. Intriguing scintillation behavior
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from LuBO3:Ce nanocrystals has been reported, with a consid-
erable dependence on the NC dimensions (Klassen et al., 2008,
2009). NC grain sizes were controlled by altering annealing
temperatures, and scintillation yields were found to increase
dramatically for NCs ∼95 nm in diameter, with roughly three
times the intensity of NCs either 25 nm larger or smaller. This
is in contrast to LuF3:Ce NPs in the same size range, which
exhibited a monotonic size dependence.
Synthesis techniques and post-synthesis processing affect the
size, crystallinity, and dopant distribution of nanostructures. The
role of post-synthesis annealing on NCs was recently investi-
gated with LaPO4:Eu and LaPO4:Pr (Malyy et al., 2013), as well
as LuPO4:Ce (Vistovskyy et al., 2014). In the case of LaPO4:Ln,
annealing was used to increase the size of the NCs, also resulting
in a change of lattice symmetry above ∼500◦C. The subsequent
effects on excitation processes over the range of 4–40 eV are
described in some detail. Across the energy range investigated,
the distinct mechanisms include intracenter excitation, charge
transfer excitation, exciton or e-h pair creation, electronic exci-
tation multiplication (E > 2 Eg), or combinations (Figure 4),
and different sensitivities were shown for the two activators—
the first stage of Eu3+ recombination involving electron capture,
in contrast to hole capture by Pr3+. With LuPO4:Ce, substantial
differences in the low energy (4–25 eV) VUV excitation spec-
trum and PL and RL decay kinetics were observed after the
NCs were annealed for 2 h at 1200◦C (vs. at 800◦C, 300◦C, or
unannealed), corresponding to an increase in the crystallite size
from 3 nm to 35 nm. The increased size resulted in well-defined
PL emission components, dramatically enhanced band-to-band
excitations above ∼8.7 eV, and the elimination of the slow RL
decay component ascribed to surface defects. Importantly, the RL
intensity for 35 nmNCs was found to be∼100× stronger than for
smaller (<12 nm)NCs, whereas the PL intensity of both types was
comparable.
The synthesis and characterization of a number of Pr3+
and Ce3+-activated garnet, silicate and oxide nanoscintillators
have recently been reported, with an emphasis on their use
for combined XRT/PDT, in particular their emission in the
300–400 nm range (Jung et al., 2014). The RL properties of
powdered nanocrystalline samples prepared through combus-
tion synthesis and annealing at 1200◦C were compared with
single/microcrystalline samples of similar compositions. The gen-
eral composition (Y1−xPrx)3Al5O12 [or yttrium aluminum gar-
net (YAG):Pr, with an average diameter of 80 nm] was found
to have the highest scintillation yield of the nanoscintilla-
tors tested under 50 keV excitation, though with a different
activator concentration dependence than single crystal sam-
ples: quenching was observed for x > 1%, compared to x =
0.16–0.65% reported for single crystals. Somewhat surprisingly,
only YAG:Pr NCs with x = 0.75, 1, and 1.5% had greater
emission intensity than Bi4Ge3O12 (BGO) NCs, in stark con-
trast to single crystals, where BGO had the lowest relative
intensity of the compositions investigated. Indeed, because the
RL behavior of NCs is dependent on activator concentration
quenching, which is in turn dependent on the NC compo-
sition, size and crystallinity, it was suggested that the prop-
erties of different preparations will likely have to be evalu-
ated individually rather than predicted by bulk trends. The
introduction of the article also provides an inclusive overview
of recent progress in nanoscintillator research for biomedical
applications.
Nanoscintillators that do not emit through specific activa-
tor ions are referred to as self-activated (SA), with lumines-
cence arising from core-valence transitions, self-trapped excitons,
FIGURE 4 | Mechanisms of scintillation in Pr3+ or Eu3+-doped LaPO4,
depending on excitation energy. (A) Intracenter (direct) excitation of Ln
activators. (B) Excitation by charge transfer from O2− to Eu3+. (C) Direct
exciton formation. (D) Creation of e-h pairs. (E) Excitation multiplication, with
secondary excitation as in (B). (F) Excitation multiplication, with secondary
excitation as in (C). (G) Photons with E > Eg can result in excitation
multiplication involving the creation of secondary e-h pairs. Arrows: (1)
Transition due to photon absorption. (2) Energy exchange due to inelastic
scattering on valence band electrons, and (3) relaxation of primary electrons.
(Reprinted with permission from Malyy et al., 2013).
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charge-transfer emissions or other mechanisms. YAG, BaF2, and
Y2O3 are among those that have been adapted to the nanoscale,
but have not yet been investigated to a large extent as SA
nanoscintillators. These compositions are also routinely doped
with other activators, resulting in various effects on their intrinsic
luminescence.
BIOCOMPATIBILITY OF LANTHANIDE-BASED MATERIALS
Preparation of LnNP bioconjugates (covalent attachment of
organic molecules of interest to the NP surface ligands) appears
infrequently in the literature. The principles of bioconjugation
are similar to those for QDs, Au, or other NPs, with some dis-
tinct stability and solubility concerns (Cao et al., 2012; Jiang
et al., 2012). Ligand-exchanged and silicated LnNPs typically
present primary amine functionalities which provide some addi-
tional versatility over carboxyl groups. Amines provide a number
of conjugation routes, including routine reactions with amine,
isothiocyanate, carboxyl, hydroxyl, and thiol functional groups on
amolecule of interest. One study reported conjugates of phospho-
rylethanolamine (PEA)-stabilized Eu3+ and Ce3+/Tb3+-doped
LaF3 by reacting the free amine of the ligandwith activated biotin-
PEG or mPEG NHS esters, demonstrating a successful strategy
for attachment of molecules through amide bond formation. The
use of these conjugates was restricted to borate buffer. Biotin
conjugates have also been prepared with CeF3:Tb NPs silanized
using TEOS/aminopropyltriethoxysilane (APTES) (Kong et al.,
2007, 2008a) and PEA-stabilized Ln3+-doped zirconia (Liu et al.,
2012).
SCINTILLATING NANOPARTICLE INTERACTIONS WITH DYES AND
PHOTOSENSITIZERS (PSs)
When nanoparticles are conjugated to PS molecules and irra-
diated with ionizing radiation, singlet oxygen yield will depend
upon scintillation yield and energy transfer efficiency. Neither
of these parameters has been widely reported in the literature.
However, a good number of studies have investigated lanthanide-
dye charge transfer using light excitation, and a few studies have
looked at singlet oxygen generation.
Lanthanide energy and charge transfer (ET and CT) have
been extensively studied for lanthanide chelates and organic dye
pairs (Selvin, 1996, 2002), and more recently in LnNPs, though
most efforts have focused on sensitization of 4f -4f lumines-
cence by Ce3+, Yb3+ or surface-associated organic molecules.
The situation can quickly become rather complex with lan-
thanides whose luminescence involves the 4f n configuration. In
these cases, magnetic dipole transitions are allowed and may
have intensity of the same order of magnitude as electric dipole
transitions. Additionally, some induced dipole transitions are
hypersensitive to the environment of the lanthanide ion and
apparently follow the selection rules of electric quadrupole tran-
sitions, leading them to be referred to as pseudo-quadrupolar
transitions.
A 2004 report investigated energy transfer between porous net-
works of interconnected 18 nm YAG:Ce3+ nanocrystals (NCs)
and the amine-reactive fluorescent dye tetramethylrhodamine
isothiocyanate (TRITC) (Wuister et al., 2004). Glycine was used
to coat the NCs, bound to the surface through the carboxy-
late moieties and providing terminal amines for attachment of
TRITC. ET for the conjugate was demonstrated through strong
emission of TRITC relative to NCs following selective excitation
of the NCs, as well as the appearance of a fast initial decay of
the time-resolved PL. The ET was estimated using Förster-Dexter
theory, giving a “critical distance” (equivalent to R0) of 7 nm,
resulting in energy transfer rates of up to 108 s−1 for Ce3+ sites
within 5 nm of the NC surface, supposed to be ∼90% of the total
Ce3+ given the NC size.
Electrostatic complexes of CePO4:Tb nanorods and
Rhodamine B (RhB), using Ce3+-sensitized Tb3+ emission
to excite RhB, resulted in ET efficiency η up to 0.85 as deter-
mined by ratiometric luminescence analysis (Di et al., 2010).
Evidence of ET was taken by the quenching of the NP steady-state
luminescence and concomitant increase in RhB emission with
increasing amounts of RhB. Time-resolved measurements of the
5D4 →7F5 transition of Tb3+ also exhibited quenching but did
not quantitatively agree, reporting efficiencies lower than those
determined by steady-state quenching (η ∼ 0.7 at the highest
quenching condition).
A recent (2013) study investigated electrostatic complexes
of LaPO4:Ce nanorods and the fluorescent dye coumarin 440
(C-440) using steady-state and time-resolved PL measurements
(Kar et al., 2013). The Stern-Volmer sphere of action static
quenching model was applied to the steady-state quenching, and
the ET efficiency estimated by the ratio of the Ce3+ fluorescence
lifetimes, giving η = 0.24 for an estimated 1:47 nanorod:dye
ratio. ET was corroborated by an increase of the fluorescence
lifetime of the dye, excited at 280 nm, when complexed with the
nanorods.
X-ray-induced singlet oxygen production has been inves-
tigated with a handful of Tb3+-activated oxide and fluoride
nanoscintillators coupled with grafted or encapsulated pho-
tosensitizers. In one study, 11-aminoundecanoic acid-coated
La0.8Tb0.2F3 NPs were mixed with the water-soluble photo-
sensitizer meso-tetra(4-carboxyphenyl) porphine (MTCP) (Liu
et al., 2008), which resulted in an increase in the quenching
rate of the anthracenedipropionic acid (ADPA) singlet oxygen
probe compared to PS alone under 250 keV X-ray irradiation at
44 cGy/min. Singlet oxygen production was demonstrated using
(Gd0.5Tb0.5)2O3 NPs with PS-encapsulating polysiloxane shells
(Seve et al., 2012). The photosensitizer 5-(4-carboxyphenyl)-
10,15,20-triphenyl-chlorin (TPC) was first conjugated to APTES
before reaction of the TPC-APTESwith TEOS for shell formation,
resulting in varied amounts of covalently bound TPC embedded
within the shell. In this case, increasing concentrations of encap-
sulated TPC resulted in quenching of the TPC PL (directly excited
at 414 nm) as well as singlet oxygen production (directly detected
through 1270 nm phosphorescence). This result was attributed
to migration of excitation energy between TPC molecules termi-
nated at static quenching sites, with a model developed to support
the data.
Recently, energy transfer mechanisms and singlet oxygen
production under optical and X-ray irradiation were stud-
ied using a similar system consisting of Gd-free Tb2O3 NPs
with the photosensitizer 5-(4-carboxyphenyl)-10,15,20-triphenyl
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porphyrin (TPP) grafted to the polysiloxane shells after rather
than during their formation (Bulin et al., 2013). The NPs and
NP-PS were used in DEG solution. Upon excitation at 300 nm
(primarily resulting in 4f8 → 4f 75d1 transitions in Tb3+), a con-
current decrease of the Tb3+ lifetimes (measured at 545 nm) and
appearance of long PL lifetimes of the grafted PS (measured at
650 nm) were taken to be indicative of excited Tb3+-PS nonra-
diative energy transfer. Interestingly, the polysiloxane layer was
implicated in the appearance of a broad emission component
from the NPs with a peak ∼425 nm that was also involved in
efficient, fast energy transfer to TPP under optical excitation,
but did not appear under X-ray excitation. Singlet oxygen yields
under 44 kV X-ray excitation (from a tungsten anode, providing
a dose rate of 5.4mGy/s) were evaluated with the chemical probes
singlet oxygen sensor green (SOSG) and 3′-p-(aminophenyl) flu-
orescein (APF). SOSG showed a steady increase in signal with
both PS alone and NP-PS, with the NP-PS showing a relative
increase for irradiation times >10min. The APF probe corrob-
orated the formation of singlet oxygen by the NP-PS system, sup-
ported by competitive quenching of singlet oxygen by addition
of NaN3.
A small number of nanoscintillator-PS conjugate systems
have demonstrated measurable enhancements of X-ray irradi-
ation in cancer cell lines. In one study, commercially available
Y2O3 NPs were modified with 2-chloroethylphosphonic acid
(2-CEP) ligands, which were used to form thioether linkages
to fragments of the HIV-1 TAT cell-penetrating/nuclear target-
ing peptide bound to the PS psoralen (Scaffidi et al., 2011).
A small but significant downward trend in the growth of PS-
3 prostate cancer cells with 2Gy of 160 kVp or 320 kVp X-rays
was seen as a function of particle dose. Another study reported
activity of a terbium-doped gadolinium oxysulfide-Photofrin II
mixture against glioblastoma cells irradiated with 120 kVp diag-
nostic X-rays. Radiation alone produced 20% cell suppression,
and radiation plus the NP-PS combination over 90% suppression.
Interestingly, the particles alone (without Photofrin) protected
the cells against X-irradiation.
A theoretical paper investigated the conditions required for
a nanoscintillator-photosensitizer conjugate system to produce
therapeutically-relevant results, using physical parameters includ-
ing nanoparticle uptake into cells, enhancement of radiation dose,
scintillation light yields, and energy transfer efficiencies (Morgan
et al., 2009). These parameters were used to estimate the over-
all singlet oxygen yield of a NP-PS system with X-ray irradiation.
As singlet oxygen is considered to be the primary effector of
PDT, its production was taken to be indicative of the potential
of conjugates to damage malignant tissue through PS activa-
tion. Overall singlet oxygen production 1O2 was determined
from the product of the scintillation yield ϕs, characteristic of
the material and given in photons per MeV of absorbed radia-
tion, the NP-PS energy transfer efficiency ϕET , and the PS singlet
oxygen yield ϕp. For an extremely generous value of ϕs > 105
photons/MeV (derived from the energy output of bulk crys-
tals of hygroscopic LuI3:Ce3+) and somewhat generous values of
ϕET = 0.75 and ϕp = 0.89, and using the relative X-ray absorp-
tion of the NPs, it was determined that to deliver the “Niedre
killing dose” of singlet oxygen (reduction of a cell population
to 1/e fraction, based on in vitro measurements of OCI-AML5
leukemia) (Niedre et al., 2002, 2003), only X-ray energies below
∼200 keV (with peak efficiency ∼50 keV) would be effective for
reasonable total radiation doses. These results suggest that it
would be difficult to produce a dramatic outcome with PDT
effects alone.
It has been established that the efficacy of PDT in vivo depends
on three primary mechanisms: direct tumor-cell killing; damage
to tumor vasculature; and provocation of an immune response
(in contrast to the immunosuppressive effects of radiotherapy
and chemotherapy (Dolmans et al., 2003). If these observations
hold true for nanoscintillator-photosensitizer systems, it is con-
ceivable that the optimal targeting and cell-level distributions of
such systemsmay be different from those that rely solely on radia-
tion dose enhancement by nanoparticles (which aremost effective
in close proximity to cell nuclei). It would also be reasonable to
expect that preserving the amphiphilicity of bioconjugated pho-
tosensitizers might be beneficial, as the tendency to associate with
lipid membranes is known to be a key factor in the activity of free
PS molecules (Kessel et al., 1987; Jori and Reddi, 1993). Whether
active targeting to tumors improves nanoparticle accumulation
in human cancers and/or treatment outcomes remains debatable.
There are certainly circumstances in which passive accumulation
is insufficient due to the physical properties of the tumor, but
the ideal target for human tumors has not been well established
(Kobayashi et al., 2013; Moghimi and Farhangrazi, 2014; Nichols
and Bae, 2014).
OTHER ALTERNATIVES: CHEMOTHERAPY-NANOPARTICLE
CONSTRUCTS
A large number of nanoparticle conjugates to chemotherapeutic
agents have been reported, but few of these have been used for
radiosensitization. This is somewhat surprising, since traditional
chemotherapeutic agents often act as radiosensitizers, and proba-
bly just reflects the emerging state of the field. A few reports have
targeted metal nanoparticles to cells or tumors using molecules
that play an active role in destroying the target cells. In one study,
radioresistant melanoma cells were exposed to Au nanorods con-
jugated to the RGD peptide (Xu et al., 2012). Exposure to MV
X-rays decreased integrin expression and rendered the cells sus-
ceptible to radiation-induced apoptosis.
Another study showed that nanoparticle preparations of
epithelial growth factor receptor (EGFR) antisense oligonu-
cleotides radiosensitized SCCVII murine squamous carcinoma
cells (Xu et al., 2012). However, the nanoparticles themselves were
a delivery vehicle only, so no synergy was being sought between
the particles and their cargo.
In another approach, doxorubicin conjugated to DNA-coated
large Au nanoparticles was loaded into MCF-7 breast cancer cells
(Starkewolf et al., 2013). Irradiation with X-rays improved cell
inhibition by 33% at 10Gy relative to Dox alone or Au nanopar-
ticles alone. The authors attributed this observation to release of
Dox by the radiation.
SUMMARY AND CONCLUSION
Dense inorganic nanoparticles show considerable promise for
dose enhancement of radiation therapy and enabling synergistic
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co-treatments. Gold nanoparticles are the most studied, though
are not yet in the clinic for radiation therapy. Research efforts
are underway to increase the efficiency of nanoparticle-based
treatments, including physical and chemical optimization of
nanoparticles, improved targeting such that total doses can be
reduced, and combining ionizing radiation with other ther-
apeutic modalities. Pre-sensitization of tumors with localized
heating resulting from illumination of Au nanostructures with
infrared light (photothermal therapy) has shown encouraging
results. A number of less expensive alternatives to Au have
been produced, but have not been subject to the same level of
research activity. Oxides and selenides of Pt and Bi have been
shown to provide radiation dose enhancement, while those of
Gd and Fe also enable magnetism-based imaging, guidance and
hyperthermia.
Nanoscintillators consist of a broad class of nanostructures
that emit light ranging from the ultraviolet to the infrared
upon excitation by ionizing radiation, with spectra that depend
primarily on composition. Energy transfer from excited state
nanoscintillators to surface-attached photosensitizer molecules
allows such a system to improve upon the issue of tissue trans-
mittance encountered with typical PDT, combined with the dose
enhancement provided by the dense nanoparticles. If the emitted
light is of an appropriate wavelength to be absorbed by photosen-
sitizer molecules, nanoscintillator-photosensitizer bioconjugates
have the potential to improve upon the issue of tissue transmit-
tance with typical PDT. Such systems have only recently been
reported, but represent another distinct class for combined ther-
apy that requires only ionizing radiation. As these systems have
thus far only been studied in vitro, and cover many possible
material compositions and drug varieties, it is difficult to reach
definitive conclusions about their advantages and disadvantages
compared to Au. While the raw materials are less expensive than
Au in general, the particles tend to be less than half as dense
as Au, and provide lower enhancement factors. While the sur-
face chemistry of Au is well established and reliable, oxide and
fluoride nanoscintillators have known colloidal stability issues.
Certainly, if XRT and PDT effects are determined to be syn-
ergistic, such systems may soon become a viable option for
nanotherapeutics.
Despite the substantial progress in nanoparticle-assisted ther-
apies in recent years, nanoscale radiosensitization effects have
not yet been studied in great detail. Further understanding
of the essential principles and interactions will help establish
the legitimacy of new undertakings in the burgeoning field of
nanomedicine, where clinical applications are just beginning to
emerge.
While a good deal of preclinical data on GNRT is avail-
able, there are not yet clinical trials in the U.S. Two types
of Au nanoparticles have been FDA approved for cancer tri-
als: Au-tumor necrosis factor conjugates (clinicaltrials.gov,
NCT00356980) and Au nanoshells for photothermal ther-
apy (AuroLase, currently recruiting, NCT01679470 and
NCT00848042 for lung cancer and head and neck cancer,
respectively). Hafnium oxide particles are in clinical trials as
radiation enhancers (NCT01433068, currently recruiting; drug
name NBTXR3).
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